Bioresorbable zinc-based drug-eluting stents for pediatric cardiovascular applications

NIH RePORTER · NIH · R01 · $733,929 · view on reporter.nih.gov ↗

Abstract

Summary This grant application is a renewal of an NIH-funded project in developing bioresorbable metallic stents in treatment of heart disease. The goal of this study is to optimize a novel bioresorbable zinc-based drug-eluting stents for pediatric cardiovascular applications and conduct comprehensive in vitro and in vivo testing to evaluate their efficacy. Coarctation of the aorta is a common heart defect in children, causing narrowing of the aorta and resulting in various symptoms. Traditional metallic drug-eluting stents are not suitable for pediatric patients due to their interference with artery development. To address this, biodegradable drug-eluting stents (BDES) are being explored. However, current materials have limitations in mechanical strength and degradation. To overcome this, a new solution called biodegradable zinc-lithium-manganese (Zn-Li-Mn) stents with a drug-eluting coating (Z- DES) has been developed. These stents offer mechanical strength, ductility, and stable biodegradation. The study aims to optimize the composition and configuration of Z-DES and evaluate its efficacy. In Aim 1, different Zn-Li-Mn alloys coated with PLLA and Sirolimus will be tested for mechanical properties and biocompatibility. Aim 2 focuses on assessing Z-DES biodegradation and safety in rat abdominal aortas. Aim 3 aims to validate Z-DES in a large animal model with narrowed aortas. The success of this research could lead to biodegradable pediatric stents that significantly improve patient outcomes and revolutionize cardiovascular interventions in children.

Key facts

NIH application ID
10904309
Project number
2R01HL140562-05
Recipient
STATE UNIVERSITY NEW YORK STONY BROOK
Principal Investigator
Ke Cheng
Activity code
R01
Funding institute
NIH
Fiscal year
2024
Award amount
$733,929
Award type
2
Project period
2018-06-01 → 2028-07-31